Lead Product(s) : E2814,Lecanemab
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. E2814 is designed to prevent the spreading of tau seeds within the brains of affected ind...
Product Name : E2814
Product Type : Antibody
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : E2814,Lecanemab
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary trial results indicated that primary endpoints were achieved with statistical significance versus placebo for subjects with chronic migraine and episodic migraine, respectively.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable